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THE ROLE AND FUNCTION OF SOX11 IN DNA DAMAGE IN TRIPLE-
NEGATIVE BREAST CANCER 
TIAN YU LEE 
ABSTRACT 
 Breast cancer is a complex heterogenous disease that consists of several different 
subtypes displaying distinct behaviors and responses to different treatments. It is the 
second leading cause of cancer death among women, and is the most commonly 
diagnosed cancer in women. Although recent developments have helped shed light into 
this disease, there is still much to investigate. One particular subtype of breast cancer, 
known as triple-negative breast cancer, remains the most aggressive, as this tumor type is 
of high histological grade and preferentially affects women with BRCA1 mutations and 
women who are younger than 40 years of age. Unlike other subtypes with better 
prognoses, triple-negative breast cancer still has no targeted therapy, and chemotherapy 
remains the primary systemic treatment. 
Recently, there has been an increase of interest in the SOXC family of high 
mobility group transcription factors and their roles in tumor development. Studies have 
revealed some of the effects that SOXC genes may have on various tumor types. 
However, further studies are still needed to elucidate the roles, functions, regulations, and 
mechanisms of these transcription factors. This study aims to focus on one particular 
gene in the SOXC family known as sex determining region Y-box 11.  Recent studies 
have shown that sex determining region Y-box 11, also known as SOX11, is one of the 
factors required for maintaining the basal-like breast cancer phenotype and is also critical 
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in regulating growth, migration, invasion, and expression of signature basal-like breast 
cancer genes. Emerging evidence also reveals that this transcription factor may have an 
impact on homologous recombination repair when DNA damage occurs, in triple-
negative breast cancer. 
Using SOX11 overexpression and knockout cell models combined with basic 
science laboratory techniques and omics, the next generation of laboratory tools, this 
study seeks to explore the role and function of SOX11 in DNA damage in triple-negative 
breast cancer.  
The results of this study have confirmed the recent findings of the role of SOX11 
in cell proliferation and growth in triple-negative breast cancer. It has also revealed that 
overexpression of SOX11 in triple-negative breast cancer cell lines leads to an increase in 
DNA damage, loss of BRCA1 function, and dysregulation in the cell cycle. High 
expression of SOX11 is also associated with worse prognostic outcomes in triple-
negative breast cancer patients. Because overexpression of SOX11 resulted in a loss of 
BRCA1 function, there may be a potential role for SOX11 in inducing the BRCAness 
phenotype commonly seen in basal-like breast cancers. The results of this study strongly 
suggest that SOX11 is involved in defective DNA damage repair pathways. Further 
studies need to be conducted in order to evaluate SOX11 as an inducer of the BRCAness 
phenotype, which occurs when there is a homologous recombination repair defect and no 
germline BRCA1 mutation present. Because of this, SOX11 may also have the potential 
to act as a functional biomarker for therapies targeting DNA damage, as recent 
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developments in identifying therapies that could potentially target homologous 
recombination repair defects have been promising.  
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1 
INTRODUCTION 
 
Breast Cancer and its Molecular Subtypes 
 Breast cancer is the most commonly diagnosed cancer in women worldwide 
(WHO, 2018) and is the second leading cause of cancer death among women in the 
United States (U.S. Cancer Statistics Working Group, 2017). Breast cancer is a 
heterogenous disease in which there are several different subtypes that display distinct 
behaviors and varying response to treatments (Polyak et al., 2007). These intrinsic breast 
cancer subtypes include luminal A, luminal B, HER2-enriched, normal-like, and triple-
negative/basal-like. (Perou et al., 2000). Among these subtypes, triple-negative breast 
cancers (TNBCs) are the most aggressive, clinically, as they are of high histological 
grade and have been shown to preferentially affect women with BRCA1 gene mutations 
as well as African-American women and women younger than 40 years of age (Reis-
Filho et al., 2008; Feng et al., 2018). TNBCs account for about 20% of all breast cancers 
and are characterized by the absence of estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal growth factor receptor 2 (HER2) expression (Feng et al., 
2018). Recent transcriptomic and genomic studies have identified further subtypes of 
TNBC-specific tumors, including two basal-like related subgroups (basal-like 1 and 2), 
one immunomodulatory group, one luminal androgen receptor group, and two 
mesenchymal related subgroups (mesenchymal and mesenchymal stem-like), of which 
the former subgroup will be the focus of this study (Bianchini et al., 2016). Basal-like 
breast cancers (BLBCs) are the most frequent subtype of TNBC (Prat et al., 2013)), and 
			
2 
more than 90% of BLBCs are TNBCs (Cheang et al., 2015). In many papers, the terms 
basal-like breast cancer and triple-negative breast cancer are often used interchangeably. 
 
Basal-Like Breast Cancer, BRCA1/2, and the BRCAness Phenotype 
BLBCs are the subtype observed in breast cancers with BRCA1 mutations 
(Livasy et al., 2006). BRCA1 and BRCA2 are proteins that are crucial in maintaining 
DNA homologous recombination repair (HRR), which repairs DNA lesions that cause 
double strand breaks and stalls in the replication fork (Venkitaraman et al., 2014). When 
either of these proteins are defective, non-conservative types of DNA repair, such as non-
homologous end joining (NHEJ), are recruited for repairing double strand breaks 
(Prakash et al., 2015). NHEJ is an error-prone repair process that involves two broken 
DNA ends being joined together, without the use of a homologous DNA sequence, 
therefore resulting in the introduction of DNA mutations (Lord et al., 2012). It has been 
shown that the continued use of NHEJ when BRCA1 or BRCA2 is absent leads to a 
higher frequency of DNA deletions, resulting in higher genomic instability and 
significantly higher risks of developing breast, ovarian, and other cancers (Tutt et al., 
2001; Couch et al., 2014). 
Only around 20% of TNBC tumors show germline or somatic BRCA1 mutations 
(The Cancer Genome Atlas Network, 2012). Yet, there are TNBC tumors with wild-type 
BRCA1 proteins that also show a deficiency in DNA repair mechanisms, and it has been 
shown that these tumors share many features with BRCA1 mutant tumors (Foulkes et al., 
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2003). This phenotype, in which there is a homologous recombination repair defect and 
no germline BRCA1 mutation present, is termed BRCAness (Lord et al., 2016). At the 
moment, it is still not clear what drives BRCAness in the majority of TNBC tumors, and 
there is no available biomarker to select for patients who may respond to therapy 
targeting BRCAness tumors. 
 
Sry-Related HMG Box Proteins 
 Sex determining region Y-box 11 (SOX11) is a transcription factor that is part of 
the SOXC family of high mobility group (HMG) transcription factors, which also 
consists of SOX4 and SOX12 (Dy et al., 2008). These proteins are characterized by the 
presence of two highly conserved functional domains, an Sry-related HMG box DNA-
binding domain at the N-terminus of the protein and a transactivation domain (TAD) 
located at the C-terminus (Dy et al., 2008). SOX11 has been found to be expressed at 
high levels in the developing central and peripheral nervous system (Hargrave et al., 
1997). Studies have also shown that SOX11 is essential in regulating the growth and 
survival of neurites and neurons, respectively (Jankowski et al., 2006). In mammary 
development, SOX11 is localized in mammary buds during epithelial-mesenchymal 
induction, suggesting a role in tissue modeling (Hargrave et al., 1997).  
Although these transcription factors were discovered more than 20 years ago (Jay 
et al., 1995, 1997), many of their molecular properties and functions are still not 
completely understood. Recently, there has been a growing interest in investigating the 
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role of SOX11 in many different tumor types in humans, as many recent reports have 
suggested that the SOXC genes may contribute to tumor prognosis. Studies have shown 
that SOX4 and SOX11 are highly expressed in most medulloblastomas (Lee et al., 2002). 
SOX11 is also highly expressed in gliomas (Weigle et al., 2005), non-B cell lymphomas 
(Wang et al., 2008), and epithelial ovarian tumors (Brennan et al., 2009). Their roles in 
cell survival, proliferation, and metastasis are still not well understood, as there seems to 
be conflicting data depending on the type of tumor involved. High expression of SOX11 
in mantle cell lymphoma (MCL) is associated with improved survival (Kuo et al., 2015). 
It has also been shown that the higher expression of SOX4 and SOX11 in 
medulloblastomas result in better prognosis (de Bont et al., 2008). However, SOX4 
knockdown resulted in apoptosis of adenoid cystic carcinoma cells (Pramoonjago et al., 
2006). A recent study has suggested that high SOX11 expression contributes to the 
progression of ductal carcinoma in situ (DCIS) to invasive breast cancer (Oliemuller et 
al., 2017). These data reveal the differing effects that SOXC genes have on various tumor 
types, and further studies are needed to elucidate these differences and roles.  
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SPECIFIC AIMS 
 In a recent study, SOX11 was identified to be one of the transcriptional factors 
required for maintaining the basal-like breast cancer phenotype (Shepherd et al., 2016). It 
was demonstrated that SOX11 is critical in regulating growth, migration, invasion, and 
expression of signature BLBC genes (Shepherd et al., 2016).  There is emerging evidence 
that the SOX11 transcription factor may also have an impact on homologous 
recombination repair during DNA damage in triple-negative breast cancer. Although 
higher genetic instability and poor prognosis is characteristic of TNBC (Nik-Zinal et al., 
2016), the underlying mechanisms are not clear. Chemotherapy remains the primary 
therapeutic approach for patients with TNBC (Bianchini et al., 2016). Due to the 
aggressive nature of this disease along with the lack of targeted therapies, there has been 
major interest in discovering molecular targets and biomarkers to target these tumors. 
Targeted agents currently under clinical investigation for TNBC include PARP inhibitors, 
PI3K inhibitors, MEK inhibitors, anti-androgen therapies, heat shock protein 90 
inhibitors, histone deacetylase inhibitors, and their combinations (Bianchini et al., 2016). 
With better understanding of the regulators and factors involved in TNBC, it could 
potentially lead to the identification of biomarkers that could target these BRCAness 
phenotype tumors and therefore result in better personalized therapy.  Using SOX11 
overexpression and knockout cell models, this study seeks to explore the role and 
function of SOX11 in homologous recombination repair in triple-negative breast cancer 
in hopes that it may have the potential to serve as a biomarker for drugs targeting DNA 
damages. 
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METHODS 
 
Cell Culture and Transfections 
All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Thermo 
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS). Stable and transient 
transfections for the creation of SOX11 overexpression cell lines were performed using 2 
μg of SOX11 human tagged ORF clone (OriGene) and 6 μL of Lipofectamine 2000 
(Thermo Fisher Scientific). Cells were seeded in a 6 well plate and after 24 hours, they 
were split in order to achieve single clones. G418 (Thermo Fisher Scientific) at 1 mg/ml 
was used for selection and generation of a stable cell line. 
 
CRISPR-Cas9 
In order to create a knockout cell model, the CRISPR-Cas9 technique was utilized. Based 
on their high endogenous levels of SOX11, cell lines Hs578T and MDA-MB-468 were 
chosen. Guide RNA (gRNA) sequences were designed with the help of 
http://crispr.mit.edu/ (Table 1). LentiCRISPR v2 (Addgene plasmid #52961) was 
digested with Esp3I (Thermo Fisher Scientific) for 1 hour at 37°C, and the digested 
plasmid was gel purified using QIAquick Gel Extraction Kit (Qiagen) and eluted in 
elution buffer. The oligonucleotides were phosphorylated and annealed in a thermocycler 
with the following parameters: 30 minutes at 37°C, 5 minutes at 95°C and then down to 
25°C, with temperature ramping down at 5°C per minute. Annealed oligonucleotides 
were diluted and a ligation reaction with the Esp3I digested plasmid was set up.  
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Table 1. gRNA sequences used to create the SOX11 knockout cell models. Primers 
were designed using http://crispr.mit.edu/.  
 
Guide RNA Score Sequence (5’ à 3’) 
#1 98 TATGGTCCAAGATCGAACGC 
#2 96 GACTGGTGCAAGACGGCGTC 
#3 95 AGACTGGTGCAAGACGGCGT 
 
Lentiviral transfer plasmids were then transformed into One Shot Stbl3 Chemically 
Competent E. coli (Invitrogen) following the manufacturer’s guidelines. Bacterial 
colonies were selected and plasmid DNA was extracted using Qiagen’s Miniprep Kit. 
Plasmid DNA samples were sent out for DNA sequencing. After sequence validation, 
NEB 5-alpha Competent E. coli (NEB) were used for further subcloning efficiency 
transformations and Maxiprep Kit (Qiagen) was used for plasmid purification. 
HEK293FT cells (Thermo Fisher Scientific) were cultured and used for transfection. 
Transfections were performed using serum-free OPTI-MEM (Thermo Fisher Scientific), 
sequence-verified CRISPR plasmid, psPAX2 (Addgene plasmid #12260), pCMV-VSV-G 
(Addgene plasmid #8454), and Lipofectamine 2000 (Thermo Fisher Scientific). Virus-
containing media was collected 48 hours after transfection, and selected cell lines were 
infected. Cells were then selected using medium supplemented with puromycin. 
Eventually, individual cell clones were isolated with the limiting dilution method, in 
which cells were diluted so that 1-2 cells/well were seeded in a 96 well plate. After 1 
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week, wells that contained a confluent 1 cell colony were further expanded into a 6 well 
plate. 
 
Western Blot 
Subconfluent cells were washed 3 times with ice-cold PBS and then lysed with lysis 
buffer supplemented with protease and phosphatase inhibitors for 10 minutes. Lysates 
were cleared by centrifugation at 15,000 g for 15 minutes at 4°C. Total protein 
concentration was determined using DC Protein Assay. Cell lysates were resolved by 4-
10% SDS-PAGE, transferred onto nitrocellulose membranes, and incubated overnight at 
4°C with the primary anti-SOX11 antibody (Abcam ab134107). Signals were detected 
using IRDye 800CW secondary antibodies (LI-COR). 
 
Wound Healing Assay 
Cells were plated and allowed to grow to 100% confluency before wounds were made by 
scraping the surface of the dish with a pipet tip. The dishes were washed and fresh media 
was added. The cells were photographed under a brightfield microscope at 40x 
magnification. They were left to grow in the incubator, and the same wound regions were 
photographed again after 24 hours. 
 
Cell Proliferation Assay 
Cells were seeded in a 96 well plate with each well containing approximately 1.5 x 103 
cells. 6 wells were used for each cell line with 100 μL of media in each well. CellTiter-
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Glo® Buffer and Substrate (Promega) were used to determine the number of viable cells 
at day 0, 1, 2, 3, and 4. 
 
RNA Purification and Quantitative PCR 
To validate the overexpression of SOX11, total RNA was extracted from cells using 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s guidelines. RNA was 
converted to cDNA and SOX11 mRNA level was determined by quantitative PCR 
(qPCR). Real-time PCR was performed in a thermocycler with the following cycling 
parameters: initial activation at 95°C for 2 minutes; denaturation at 95°C for 5 seconds, 
annealing at 60°C for 30 seconds and then this was repeated for a total of 40 cycles. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the reference gene. 
 
Immunofluorescence Staining 
Cells were plated on a coverslip and incubated in a 37°C incubator so that they could 
attach and spread. After incubation, the cells were fixed with 3% formaldehyde, washed 3 
times, permeabilized with 0.5% Triton X-100, washed 3 more times, and stained with 
Alexa Fluor® 488 (Invitrogen), an anti-SOX11 antibody, in 10% donkey serum, 
overnight at 4°C. After washing 3 times, cells were incubated with Alexa Fluor® 594 
donkey anti-rabbit IgG antibody (Invitrogen). VECTASHIELD® mounting medium with 
DAPI (Vector Laboratories) was used for DAPI counterstaining and mounting. Images 
were taken using an immunofluorescence (IF) microscope.  
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Proteomics Study 
Whole cell lysate was collected and sent out to the Mass Spectrometry and Biomarker 
Discovery Core at Cedars-Sinai Medical Center for quantitative proteomics analysis. 
Ingenuity Pathway Analysis® (IPA; Qiagen) software was then used to interpret the data. 
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RESULTS 
  
 Using the Kaplan Meier (KM) plotter, the study assessed the effect of 
SOX11 on survival probability across various cancer types. Among the majority of 
cancer types analyzed, high expression of SOX11 was associated with poor survival. This 
was evident in breast cancer, cervical squamous cell carcinoma, sarcoma, ovarian cancer, 
pancreatic ductal adenocarcinoma, kidney renal papillary cell carcinoma, bladder 
carcinoma, liver hepatocellular carcinoma, and uterine corpus endometrial carcinoma 
(Figure 1, 2). The reverse trend, in which high expression of SOX11 was associated with 
better prognosis, was seen in lung squamous cell carcinoma, rectum adenocarcinoma, and 
thymoma (Figure 2).  
Analyzing the effect of SOX11 expression in breast cancer patients showed that 
high SOX11 expression levels led to a lower probability of survival (Figure 3). This was 
the case in overall survival, recurrence-free survival, post-progression survival, and 
distant metastasis-free survival. This data is also consistent with the pattern seen when 
analyzing cases of SOX11 overexpression using the Cancer Genome Atlas (TCGA). The 
analysis of SOX11 expression in breast cancer patients showed that cases with SOX11 
overexpression led to a lower probability of survival (Figure 4).  
When looking specifically at triple-negative breast cancer, there was a definite 
association between high SOX11 expression and worse prognosis when analyzing overall 
survival, regression-free survival, and distant metastasis-free survival rates in TNBC 
patients using Kaplan-Meier plot analysis (Figure 5).
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Figure 1. Kaplan-Meier plot analysis of SOX11 expression in various cancer types. Analysis of the various cancers 
above shows that high SOX11 expression is associated with poor prognosis. All survival data was taken from the Curtis 
dataset (Curtis et al., 2012) and/or the Pereira dataset (Pereira et al., 2016). 
 
Breast Cancer Cervical Squamous Cell Carcinoma Sarcoma
Ovarian Cancer Pancreatic Ductal Adenocarcinoma Kidney Renal Papillary Cell Carcinoma
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Figure 2. Continuation of Kaplan-Meier plot analysis of SOX11 expression in various cancer types. The first row 
of plots shows that in those cancers, higher levels of SOX11 are associated with a lower probability of survival while 
the second row of cancers analyzed displays the opposite trend. All survival data was taken from the Curtis dataset 
(Curtis et al., 2012) and the Pereira dataset (Pereira et al., 2016). 
Bladder Carcinoma Liver Hepatocellular Carcinoma
Lung Squamous Cell Carcinoma Rectum Adenocarcinoma
Uterine Corpus Endometrial Carcinoma
Thymoma
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Figure 3. Kaplan-Meier plot analysis of SOX11 expression in breast cancer patients. Analysis shows that high 
SOX11 expression is associated with lower overall survival (OS), recurrence-free survival (RFS), post-progression 
survival (PPS), and distant metastasis-free survival (DMFS). All survival data was taken from the Curtis dataset (Curtis 
et al., 2012) and/or the Pereira dataset (Pereira et al., 2016).
OS RFS
PPS DMFS
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Figure 4. TCGA database analysis of SOX11 expression in breast cancer patients. 
Breast cancer patients without SOX11 overexpression showed higher survival rates than 
those with SOX11 overexpression.  
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Figure 1. TCGA database analysis of SOX11 
expression in breast cancer patients.
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Figure 5. Kaplan-Meier plot analysis of SOX11 expression in basal-like breast cancer patients. It is evident that 
there is a clear association between high SOX11 expression and a lower probability of survival in all categories: OS, 
RFS, and DMFS. All survival data was taken from the Curtis dataset (Curtis et al., 2012) and/or the Pereira dataset 
(Pereira et al., 2016).
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RFS
Basal -
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The study analyzed the expression of SOX11 in several breast cancer cell lines 
and normal mammary epithelial cells (Figure 6). SOX11 was expressed in some HER2-
enriched and basal-like breast cancer cell lines. As expected, SOX11 was not found in 
normal epithelial cell lines. 
Using western blot analysis, SOX11 overexpression and knockout clones were 
confirmed to have overexpression and no expression of SOX11, respectively. Additional 
experiments were run to validate these results, including IF staining and qPCR (Figure 7, 
8). 
 
 
 
 
Figure 6. Western blot analysis of SOX11 expression in breast cancer and normal 
mammary epithelial cell lines. SOX11 expression is not seen in normal mammary 
epithelial cell lines. Actin was used as a loading control.  
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Figure 7. IF staining confirms the overexpression of SOX11 in the MDA-MB-436 
SOX11 overexpression cell line model. This was taken at 400x magnification. Alexa 
Fluor® 488 (AF488) was used to visualize the localization of SOX11 protein (green). 
Nuclei were stained with DAPI (blue). 
 
                
 
Figure 8. IF staining confirms the knockout of SOX11 in the Hs578T SOX11 
knockout cell line model. This was taken at 400x magnification. Alexa Fluor® 488 
(AF488) was used to visualize the localization of SOX11 protein (green). Nuclei were 
stained with DAPI (blue). 
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 Cell proliferation for the SOX11 overexpression and knockout cell lines was 
assessed (Figure 9). The MDA-MB-468 SOX11 knockout cell line showed higher cell 
viability compared to its parental line while the Hs578T SOX11 knockout cell line 
showed lower cell viability when compared to its parental line. Over a period of 1 week, 
cell proliferation for MDA-MB-436 SOX11 overexpression clones was measured with 
two of the clones, #5 and #33, showing lower cell proliferation, and clone #34 showing 
similar cell proliferation rates, when compared to its parental cell line.  
A wound healing assay was conducted in parental cell lines BT549 and MDA-
MB-231, and their respective overexpression clones to determine cell migration rates 
(Figure 10). The overexpression of SOX11 in cell lines BT549 and MDA-MB-231 led to 
increased cell migration and rate of “healing” of the gap after a period of 24 hours when 
compared to their respective parental cell line.  
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Figure 9. Cell growth curve of SOX11 overexpression and knockout cell lines. MDA-
MB-468 SOX11 knockout model showed a higher cell proliferation rate compared to its 
parental line while the Hs578T SOX11 knockout model showed a lower cell proliferation 
rate compared to its parental line. Cell proliferation rates for three MDA-MB-436 SOX11 
overexpression clones were assessed for a week, with clones #5 and #33 showing lower 
cell viability when compared to its parental line. MDA-MB-436 SOX11 overexpression 
clone #34 showed similar cell proliferation rates compared to its parental cell line. 
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Figure 10. Wound healing assay on BT549, BT549 SOX11 overexpression clone #3, 
MDA-MB-231, and MDA-MB-231 SOX11 overexpression clone #11. Images of 2 
separate wound regions were captured after 24 hours on a brightfield microscope. 
Overexpression clones visibly showed more aggressive cell migration in comparison to 
their parental line. 
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Proteomics study of MDA-MB-231 SOX11 overexpression cell model and MDA-
MB-231 parental cell line showed that overexpression of SOX11 leads to the induction of 
many signaling pathways, including integrin signaling, glioma invasiveness signaling, 
phospholipase C signaling, tec kinase signaling, CDK5 signaling, and ceramide signaling. 
What is especially important to note is that SOX11 overexpression leads to significant 
changes in DNA damage and repair pathways, including cell cycle de-regulation, loss of 
BRCA1 function, and aneuploidy. This is evident in the activation of G2/M phase DNA 
damage, NRF2-mediated oxidative stress response, and survival AKT pathways (Figure 
11). SOX11 overexpression also leads to the suppression of BRCA1 in DNA damage 
response, apoptosis, and cell cyclin regulation. IPA analysis of the cellular functions in 
DNA damage repair and cell cycle regulation in MDA-MB-231 SOX11 overexpression 
cells showed that many of the functions were significantly affected, including aneuploidy 
and chromosomal aberration (Figure 12).  
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Figure 11. Most significant signaling pathways highly induced and suppressed in 
SOX11 overexpressed MDA-MB-231 cells. Absolute ratio >1.5 was selected as the 
cutoff for IPA analysis. Activation Z score of up and down-regulated pathways is seen.  
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Figure 12. Significant cell functions induced in DNA damage repair and cell cycle 
regulation in SOX11 overexpression MDA-MB-231 cells. Absolute ratio >1.5 was 
selected as the cutoff for IPA analysis.  
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DISCUSSION 
 
 Recent reports have suggested that the SOXC genes may contribute to tumor 
prognosis. Although the role and mechanism of these genes in cell survival, proliferation, 
and metastasis are still not well understood, it is becoming more and more evident that 
SOX11 plays a crucial role in BLBC. Based on the results of other studies, as well as this 
one, it is important to note that the expression level of SOX11 varies across different 
tumor types and is therefore associated with different prognostic outcomes. From this 
study, it is clear that high expression of SOX11 in TNBC patients is associated with 
worse prognosis and lower chances of survival. 
Several cell lines were used to create the SOX11 overexpression and knockout 
cell models in order to best determine the effects of SOX11 on BLBC. The study hoped 
to combine the findings from several different TNBC cell models in order to best present 
the most representative role of SOX11 in BLBC. Based on the wound healing assay, high 
levels of SOX11 resulted in more aggressive cell migration, further supporting evidence 
of SOX11’s role in tumor metastasis. The study expected SOX11 overexpression cell 
models to show higher cell proliferation rates and SOX11 knockout cell models to show 
lower cell proliferation rates. This trend was seen in the Hs578T SOX11 knockout cell 
line. However, cell proliferation rates for the MDA-MB-468 SOX11 knockout cell line 
and MDA-MB-436 SOX11 overexpression cell line was not as expected. The varying 
results may be impacted by the minute differences among the cell lines. However, further 
studies are needed to look into this discrepancy. 
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Data analyzing the differentially expressed proteins between SOX11 
overexpression and vector control cells showed that there was an increase in DNA 
damage, dysregulation in the cell cycle, and loss of BRCA1 function in cells that 
overexpressed SOX11. This would ultimately lead to increased mutations and higher 
genomic instability, and confirms the finding that high expression of SOX11 is associated 
with a lower probability of survival. The study focused on BRCA1 wildtype TNBC cell 
lines. Yet even with these wildtype BRCA1 proteins, it was seen through the proteomics 
study that the overexpression of SOX11 resulted in a loss of BRCA1 function. Thus, 
there may be a potential role for SOX11 in inducing the BRCAness phenotype commonly 
seen in many TNBCs. The results of the study strongly suggest SOX11’s involvement in 
defective BRCA1 function and DNA damage repair pathways. Further studies need to be 
performed to evaluate SOX11 as an inducer of the BRCAness phenotype and as a 
functional biomarker for therapies targeting DNA damage. Recent developments in 
identifying therapies that could potentially target HRR defects are promising.  
Although this study has shown that SOX11 plays a definite role in DNA damage, 
cell survival, and cell proliferation in TNBC, further studies need to be conducted to 
explore the mechanism and regulation of SOX11.  
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